Eagle Health Holdings Limited (ASX:EHH) (Eagle Health or Company) continues its multi-dimensional integration of opportunities in a deliberate strategy matrix of geographic, production and marketing opportunities.

To assist in the facilitation of this plan, the Company has engaged Sydney based corporate advisory firm, Crestbridge Capital Pty Ltd (“Crestbridge”) to assist the Company and act as Corporate Advisors and Transaction Facilitators as EHH seeks to aggressively implement the acquisition component of its growth model.

Crestbridge will work with Mr. Zhang, Managing Director of Eagle Health and his corporate team to source, secure and execute value accretive merger and acquisition opportunities for the Company.

Crestbridge will also work towards creating greater market awareness of EHH and recommend capital project funding options.

EHH recently announced expansion plan in its Traditional Chinese Medicine(“TCM”) product range and offering. Integral to that announcement is the plan to source natural, reliable, high quality raw materials and establish TCM production, including Hemp, facilities from Australia.

Crestbridge will work with Mr. Zhang, Managing Director of Eagle Health and his corporate team to source, secure and execute value accretive merger and acquisition opportunities for the Company.

Crestbridge will also work towards creating greater market awareness of EHH and recommend capital project funding options.

EHH recently announced expansion plan in its Traditional Chinese Medicine(“TCM”) product range and offering. Integral to that announcement is the plan to source natural, reliable, high quality raw materials and establish TCM production, including Hemp, facilities from Australia.

Click for more information